Publications by authors named "Isaac D Hoffman"

Claim this Profile
D
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia.
Robert L Hudkins, Eric Allen, Alexandra Balcer, Isaac D Hoffman, Samhita Iyer

J Med Chem· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.
Jun Fujimoto, Osamu Kurasawa, Terufumi Takagi, Xin Liu, Hiroshi Banno, Isaac D Hoffman

ACS Med Chem Lett· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
Mitsunori Kono, Atsuko Ochida, Tsuneo Oda, Takashi Imada, Yoshihiro Banno, Isaac D Hoffman

J Med Chem· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
Satoshi Mikami, Masanori Kawasaki, Shuhei Ikeda, Nobuyuki Negoro, Shinji Nakamura, Isaac Dylan Hoffman

Chem Pharm Bull (Tokyo)· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
Satoshi Mikami, Shinji Nakamura, Tomoko Ashizawa, Izumi Nomura, Masanori Kawasaki, Isaac D Hoffman

J Med Chem· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure.
Tomohiro Okawa, Yoshio Aramaki, Mitsuo Yamamoto, Toshitake Kobayashi, Shoji Fukumoto, Isaac D Hoffman

J Med Chem· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Betty Lam, Yasuyoshi Arikawa, Joshua Cramlett, Qing Dong, Ron de Jong, Isaac D Hoffman

Bioorg Med Chem Lett· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein crystallization for structure-based drug design.
Isaac D Hoffman

Methods Mol Biol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of Inhibition of Novel Tryptophan Hydroxylase Inhibitors Revealed by Co-crystal Structures and Kinetic Analysis.
Giovanni Cianchetta, Terry Stouch, Wangsheng Yu, Zhi-Cai Shi, Leslie W Tari, Isaac D Hoffman

Curr Chem Genomics· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors.
Leslie W Tari, Isaac D Hoffman, Daniel C Bensen, Michael J Hunter, Jay Nix

Bioorg Med Chem Lett· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis